Extracellular Vesicles as Mediators of Cancer Disease and as Nanosystems in Theranostic Applications

Simple item page
dc.contributor.authorBurgos, Renato
dc.contributor.authorCampos, América
dc.contributor.authorDíaz, Magda
dc.contributor.authorGonzález, María Fernanda
dc.contributor.authorLeón, Daniela
dc.contributor.authorLobos-González, Lorena
dc.contributor.authorLeyton, Lisette
dc.contributor.authorKogan, Marcelo
dc.contributor.authorQuest, Andrew
dc.date.accessioned2022-03-23T20:10:29Z
dc.date.available2022-03-23T20:10:29Z
dc.date.issued2021
dc.description.abstractCancer remains a leading cause of death worldwide despite decades of intense efforts to understand the molecular underpinnings of the disease. To date, much of the focus in research has been on the cancer cells themselves and how they acquire specific traits during disease development and progression. However, these cells are known to secrete large numbers of extracellular vesicles (EVs), which are now becoming recognized as key players in cancer. EVs contain a large number of different molecules, including but not limited to proteins, mRNAs, and miRNAs, and they are actively secreted by many different cell types. In the last two decades, a considerable body of evidence has become available indicating that EVs play a very active role in cell communication. Cancer cells are heterogeneous, and recent evidence reveals that cancer cell-derived EV cargos can change the behavior of target cells. For instance, more aggressive cancer cells can transfer their “traits” to less aggressive cancer cells and convert them into more malignant tumor cells or, alternatively, eliminate those cells in a process referred to as “cell competition”. This review discusses how EVs participate in the multistep acquisition of specific traits developed by tumor cells, which are referred to as “the hallmarks of cancer” defined by Hanahan and Weinberg. Moreover, as will be discussed, EVs play an important role in drug resistance, and these more recent advances may explain, at least in part, why pharmacological therapies are often ineffective. Finally, we discuss literature proposing the use of EVs for therapeutic and prognostic purposes in cancer.es
dc.description.versionVersión publicada
dc.identifier.citationBurgos-Ravanal, R.; Campos, A.; Díaz-Vesga, M.C.; González, M.F.; León, D.; Lobos-González, L.; Leyton, L.; Kogan, M.J.; Quest, A.F.G. Extracellular Vesicles as Mediators of Cancer Disease and as Nanosystems in Theranostic Applications. Cancers 2021, 13, 3324. https://doi.org/ 10.3390/cancers13133324es
dc.identifier.urihttps://doi.org/ 10.3390/cancers13133324es
dc.identifier.urihttp://hdl.handle.net/11447/5786
dc.language.isoenes
dc.subjectextracellular vesicleses
dc.subjecthallmarks of canceres
dc.subjectdrug resistancees
dc.subjecttheranosticses
dc.titleExtracellular Vesicles as Mediators of Cancer Disease and as Nanosystems in Theranostic Applicationses
dc.typeArticlees
dcterms.sourceCancerses

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Extracellular Vesicles as Mediators of Cancer Disease and as.pdf
Size:
3.08 MB
Format:
Adobe Portable Document Format
Description:
Texto completo
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Artículos Medicina y Ciencias de la Salud

Implementado por OpenGeek Services